1. EPWORTH Knowedge Bank
  2. Academic & Clinical
  3. Cancer Services
Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/827
Full metadata record
DC FieldValueLanguage
dc.contributor.advisor​UroRenal & Vascular Clinical Institute, Epworth HealthCare, Richmond, Victoria, Australia-
dc.contributor.authorMurphy, Declan-
dc.contributor.otherZargar, Homayoun-
dc.date2016-03-
dc.date.accessioned2016-10-25T04:04:39Z-
dc.date.available2016-10-25T04:04:39Z-
dc.date.issued2016-
dc.identifier.citationEur Urol. 2016 Mar;69(3):540en_US
dc.identifier.issn0302-2838en_US
dc.identifier.urihttp://hdl.handle.net/11434/827-
dc.descriptionComment on Chemohormonal 'Therapy in Metastatic Hormone-Sensitive Prostate Cancer.'. Sweeney CJ, Chen YH, Carducci M, et al, N Engl J Med 2015;373:737–46.en_US
dc.description.abstractExperts’ summary: This landmark study of men with advanced prostate cancer tested the hypothesis that addition of docetaxel chemotherapy (DC) to androgen deprivation therapy (ADT) at the time of treatment initiation would lead to improved overall survival in men with metastatic prostate cancer (CHAARTED trial). A total of 790 men were randomised. At a median follow-up of 29 mo, overall survival was 13.6 mo longer in the ADT + DC group than for ADT alone (57.6 vs 44.0 mo; hazard ratio [HR] 0.61, 95% confidence interval [CI] 0.47–0.80; p < 0.001). Furthermore, among men with high-volume metastatic disease, the median overall survival was 17.0 mo longer in the ADT + DC group than for ADT alone (49.2 vs 32.2 mo; HR 0.60, 95% CI 0.45–0.81; p < 0.001). Overall, the combined treatment was quite well tolerated.en_US
dc.publisherElsevieren_US
dc.subjectProstate Canceren_US
dc.subjectMetastatic Prostate Canceren_US
dc.subjectChemohormonal Therapyen_US
dc.subjectCHAARTED Protocolen_US
dc.subjectAndrogen Deprivation Therapyen_US
dc.subjectADTen_US
dc.subjectDocetaxel Chemotherapyen_US
dc.subjectSurvival Ratesen_US
dc.subjectAustralian Prostate Cancer Research Centre, Epworth HealthCare, Victoria, Australiaen_US
dc.subjectCancer Services Clinical Institute, Epworth HealthCare, Victoria, Australia-
dc.titleWords of wisdom re: Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.en_US
dc.typeCommenten_US
dc.identifier.doidoi: 10.1016/j.eururo.2015.12.027en_US
dc.identifier.journaltitleEuropean Urologyen_US
dc.description.pubmedurihttps://www.ncbi.nlm.nih.gov/pubmed/26867727en_US
dc.description.affiliatesDepartment of Urology, Royal Melbourne Hospital, Melbourne, Australiaen_US
dc.description.affiliatesDivision of Cancer Surgery, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australiaen_US
dc.description.affiliatesDepartment of Urology, Royal Melbourne Hospital, Melbourne, Australiaen_US
dc.type.contenttypeTexten_US
Appears in Collections:Cancer Services
Epworth Prostate Centre
UroRenal, Vascular

Files in This Item:
There are no files associated with this item.
Show simple item record


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.